NextRNA Therapeutics

NextRNA Therapeutics, Inc. is a Massachusetts-based biotechnology startup founded in 2020, focused on driving the next revolution of RNA-directed therapeutics. The company has positioned itself as a leader in the industry with a proprietary target and drug discovery engine, stemming from the groundbreaking work of Carl Novina at Dana-Farber Cancer Institute.

NextRNA Therapeutics has received a significant boost with a $46.80M Series A investment on 01 March 2022, attracting backing from an impressive list of investors including Circle Alternative Investments, CoBro Ventures, Jefferies, Lightchain Capital, Rivas Capital, Willett Advisors, and Evans Capital.

The company's focus on identifying disease-relevant long non-coding RNAs and developing selective small molecules to target RNA-protein interactions has led to the advancement of two small molecule therapeutic programs in oncology and immunology.

Utilizing a team comprising industry leaders, biology and chemistry experts, and drug developers, NextRNA is poised to make a significant impact in the field of biotechnology and healthcare, driven by a passion for science and a commitment to improving patient outcomes.